Body composition during treatment with lumacaftor/ivacaftor in 24 adults# with cystic fibrosis

Baseline1 month6 months1 yearp-value
Weight kg58.4±12.159.0±11.360.6±10.9**60.8±11.10.0007
Fat-free mass kg46.1±11.245.8±10.946.7±11.046.2±10.70.49
Fat mass kg12.5±6.713.5±6.414.0±5.8**14.7±6.3***<0.0001
BMI kg·m−220.3±2.720.5±2.421.1±2.1*21.2±2.3**0.0003
FFMI kg·m−215.9±2.515.8±2.416.1±2.416.0±2.30.48
FMI kg·m−24.4±2.44.8±2.44.9±2.2**5.2±2.4***<0.0001
TBW L33.7±8.133.6±7.734.2±7.933.9±7.80.46
ICW L19.2±5.519.2±5.519.7±5.319.5±5.20.27
ECW L14.5±2.814.4±2.714.5±2.814.4±2.80.84
ECW % TBW43.6±3.943.3±3.442.8±3.843.0±3.50.29
Phase angle °4.8±0.94.8±0.94.7±1.44.8±0.90.08

Data are presented as mean±sd, unless otherwise stated. BMI: body mass index; FFMI: fat-free mass index; FMI: fat mass index; TBW: total body water; ICW: intracellular water; ECW: extracellular water. #: n=24 for weight and BMI for all time-points, and for all data at 1 year; n=23 for all other measurements at baseline, 1 month and 6 month time-points (for one patient, useable bioelectrical impedance analysis could not be obtained at baseline and 1 month, and one patient missed the 6-month measurement). Individual p-values for change between baseline and that time-point (derived from the regression model with Bonferroni correction): *: p<0.05; **: p<0.005; ***: p<0.0001. Overall p-value is for the linear mixed effects regression model for effect of time on variables.